Background; Treatmet of coronary in-stent restenosis (ISR) is still high incidence of recurrence of ISR. We aimed to assess the efficacy and safety of a paclitaxel-coated balloon treatment in ISR. Methods; We enrolled 46 patients (53 lesions, male 56.5%, mean age 64.5짹10.6 years) which treated with drug eluting balloon (DEB) from January 2010. The primary end point was major adverse cardiac events (cardiac death, myocardial infaction, target lesion revascularization ) and stent thrombosis. Result; We treated 46 patients, 53 ISR lesions (LAD/LCX/RCA; 43.4/15.1/35.8%, ISR type Ia/Ib/Ic/Id/II/III/IV; 0/22.6/26.4/28.313.2/0/3.8%). 42 patients were treated with the DEB (meandiameter/length/pressure/time; 3.0짹0.3mm/21.2짹4.3mm/10.6짹2.4atm/46.5짹25.9sec) only, while 4 patients (7.5%) required additional BMS stent deployments. Mean clinical follow up was 10.2 month. During the follow up, there was one cardiac death (2.2%), two noncardiac deathes (4.3%), one myocardial infaction (2.2%), and one target lesion revascularization (2.2%) but no stent thrombosis. And total major adverse cardiac events were three (6.5%). Conclusion; Treatment of coronary in-stent restenosis with DEB showed feasible and relatively low MACE in small and short-term of this study. But large and long term clinical and angiographical follow up will be needed.